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Abstract
Purpose Sacral neuromodulation has been reported as a
treatment for severe idiopathic constipation. This study
aimed to evaluate the long-term effects of sacral neuro-
modulation by following patients who participated in a
prospective, open-label, multicentre study up to 5 years.
Methods Patients were followed up at 1, 3, 6, 12, 24, 36,
48 and 60 months. Symptoms and quality of life were
assessed using bowel diary, the Cleveland Clinic consti-
pation score and the Short Form-36 quality-of-life scale.
Results Sixty-two patients (7 male, median age 40 years)
underwent test stimulation, and 45 proceeded to permanent
implantation. Twenty-seven patients exited the study (7
withdrawn consent, 7 loss of efficacy, 6 site-specific rea-
sons, 4 withdrew other reasons, 2 lost to follow-up, 1 prior
to follow-up). Eighteen patients (29%) attended 60-month
follow-up. In 10 patients who submitted bowel diary, their
improvement of symptoms was sustained: the number of
defecations per week (4.1 ± 3.7 vs 8.1 ± 3.4, mean ± s-
tandard deviation, p\ 0.001, baseline vs 60 months) and
sensation of incomplete emptying (0.8 ± 0.3 vs 0.2 ± 0.1,
p = 0.002). In 14 patients (23%) with Cleveland Clinic
constipation score, improvement was sustained at
60 months [17.9 ± 4.4 (baseline) to 10.4 ± 4.1,
p\ 0.001]. Some 103 device-related adverse events were
reported in 27 (61%).
Conclusion Benefit from sacral neuromodulation in the
long-term was observed in a small minority of patients with
intractable constipation. The results should be interpreted
with caution given the high dropout and complication rate
during the follow-up period.
Keywords Sacral neuromodulation  Sacral nerve
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Background
Constipation is one of the common bowel disorders seen in
daily clinical practice. The prevalence is estimated to be
around 14% with significant impact on quality of life, in
some patients to debilitating effect [1].
The initial management of constipation is lifestyle
advice such as sufficient fluid and fibre intake although the
evidence is poor. Use of laxatives is common but often not
judicious and many patients remain refractory to currently
available laxatives. Prucalopride and other recently avail-
able prokinetic drugs are effective for some patients in
short term [2], but their efficacy may not be sustained in the
long term. Behavioural treatment (biofeedback) is effective
for many patients in a randomized trial, but some remain
symptomatic [3, 4].
Bowel irrigation can be utilized either retrograde (via
anus) or antegrade via creation of irrigation stoma (ap-
pendicostomy or caecostomy) which in some patients
exacerbates sensation of bloating and abdominal pain.
Traditional surgical approach has been colectomy with
stoma formation which is associated with complications
and necessitates life-long use of stoma bags and should
only be considered once all other options have been
exhausted [5].
Sacral neuromodulation (SNM) is a minimally invasive
treatment which has become an established option for
faecal incontinence over the last decade in Europe. Ganio
et al. [6] first reported improvement of constipation in
patients treated by SNM. Since then a few other studies
emerged that SNM may be efficacious for constipation
refractory to conventional treatment [7–11]. However, the
follow-ups have been in general short- or medium-term and
there is a paucity of knowledge of treatment outcome in the
long term.
This study aimed to evaluate the outcome of SNM for
constipation refractory to medical and behavioural treat-
ment over the 5-year study period.
Methods
Data have been prospectively collected in an open-label,
multicentre study to evaluate the clinical efficacy and safety
of sacral neuromodulation for chronic intractable constipa-
tion. Data were recorded up to 60-month follow-up. Study
methods, including baseline investigations, the definition of
constipation, inclusion and exclusion criteria, and operative
details have been reported previously [11]. Briefly, data
collected at baseline included patient demographics, bowel
diary, patient’s rating of his/her bowel habit on a visual
analogue scale (VAS), Cleveland Clinic constipation score
(CCCS, Wexner Constipation Score) [12], 36-item Short
Form Health Survey (SF-36) [13] and use of medication.
Inclusion criteria were as follows: (a) age between 18 and
75 years, (b) chronic constipation documented by baseline
diary 3 weeks as defined by two or fewer bowel movements
per week on average and/or impaired defecation defined as
[25% of all visits to the bathroom (attempts to defecate)
subject had to strain and/or[25%of all visits to the bathroom
subject did not feel empty afterwards (incomplete evacua-
tion), (c) symptoms of constipation present for aminimumof
1 year, (d) failed maximal medical therapy such as dietary
modifications, laxatives and enemas, (e) failed biofeedback
therapy within 1 year before enrolment. Exclusion criteria
were (a) any organic pathology that may be causing consti-
pation and requiring surgical intervention, (b) congenital
anorectal malformations, (c) previous large bowel surgery
including rectal prolapse repair, (d) present rectal prolapse,
(e) chronic bowel diseases such as inflammatory bowel
disease, (f) inconsistent bowel habit, associated with alter-
nating constipation and diarrhoea, (g) stoma in situ,
(h) neurological diseases, such as complete spinal cord
transection, multiple sclerosis, spina bifida and Parkinson’s
disease, (i) subjects who have a significant psychological and
social element to their symptoms as judged by the investi-
gator, (j) bleeding complications, (k) pregnancy,
(l) anatomical limitations which would prevent successful
placement of an electrode, (m) skin and tissue diseases with
the risk of infection such as pyoderma and untreated pilo-
nidal sinus.
All patients underwent a 3-week test stimulation with
the InterStim model 3057 lead prior to permanent device
implantation. It should be noted that the CE mark approved
duration for test stimulation with the model 3057 lead is
7 days. For the purpose of this trial, the lead was specifi-
cally marked as investigational device allowing up to
30 day of test period. Competent authorities were
informed. Criteria to proceed to permanent implantations
were as follows: (1) weekly average of bowel movements
improved to C3 without increase of laxatives, enemas or
manual stimulation, and/or (2) C50% of the number of
episodes with impaired defecation (straining or incomplete
evacuation depending on the clinical situation at baseline).
After permanent device implantation, patients were
followed up at 1, 3, 6, 12, 24, 36, 48 and 60 months using
the same set of questionnaires. Anorectal physiological
testing was performed at each follow-up. Programming
changes were done as per standard clinical practice as and
when needed to optimize the therapy. Colonic transit study
and evacuation proctogram were repeated at 6 months
post-implant. Therapeutic efficacy of permanent SNM was
evaluated by comparing baseline with post-implant data
obtained at follow-up visits.
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Adverse events
All adverse events during the study were documented,
regardless of whether they were related to the treatment.
Events were classified as serious and non-serious adverse
events or an adverse device effect according to ISO 14155.
Each event was further rated as mild, moderate or severe.
Statistical analysis
The principle of intention to treat (ITT) was used to analyse
the data for outcome. This meant that all participants who
underwent PNE in the study were included in the analysis.
The proportion of patients at each follow-up is expressed in
both ITT and per protocol analysis (PP) that included only
those subjects who underwent an implantation of device.
This approach was used to measure the effects of SNM on
constipation and to reflect what would happen in clinical
practice.
Data are presented as mean and standard deviation when
normally distributed and median and range when not nor-
mally distributed. When data distribution changed over
follow-up period, both sets of data are presented. Quanti-
tative or continuous data are summarized by descriptive
statistics as number of values, while qualitative or discrete
data are summarized as frequency and percentage of
patients in each class variable.
All analyses of the efficacy variables were performed by
fitting a generalized estimating equations (GEE) model for
repeated data based on a normal distribution. The model
had the efficacy variables as dependent variables and
baseline values and visits as explanatory variables.
The efficacy variables could have been pre-log trans-
formed depending on their normal or non-normal distri-
bution. The visits explanatory variables were considered as
a qualitative variable with baseline visit as the reference
level. SAS PROC GENMOD was used to conduct the GEE
analysis using an unstructured correlation structure. Dif-
ference between visits means was tested by applying con-
trast on the estimated GEE model.
Statistical tests were two-sided, and a p value of less
than 0.05 was considered statistically significant. Since this
was an exploratory study, no imputation was implemented
for missing follow-up data. The bowel diary did not dif-
ferentiate a day without defecation from a day with missing
data. Bowel diary data were handled as follows: (1) mon-
itored days were defined as days for which there was at
least one entry for any of the variables, (2) in case no data
were collected for one or more days in the diary, these days
were considered as missing days and no imputation was
implied, (3) in case data from the diary were missing for a
whole visit, no imputation was implemented and the diary
was considered missing.
For the CCCS questionnaire, imputation was performed
when data were not available for all items of the ques-
tionnaire as follows: (1) when one or several items of the
Wexner score were missing for a completed visit, impu-
tation of data using the last observation carried forward
(LOF) approach was used (the last observation had to
originate from a post-baseline visit), (2) when the entire
CCCS score was missing for a completed visit, no impu-
tation was implemented and the score value considered as
missing.
No imputation was applied for missing data from the
SF-36 questionnaire, as SF-36 scores can be computed
from incomplete SF-36 questionnaires through standard
SF-36 algorithms.
In case a subject terminated the study early, no impu-
tation was implemented for the missing visits.
Results
The study was started in January 2002 and completed in
December 2012. Sixty-two (62) patients (7male, median age
of 40, range 17–79) at 5 European centres [St Mark’s
Hospital, London, UK (30 patients); Maastricht University
Medical Centre, Maastricht (17), The Netherlands; Aarhus
University Hospital, Aarhus, Denmark (8); Danderyd
Hospital, Stockholm, Sweden (4); and Danube Hospital,
Vienne, Austria (3)] were enrolled in the study and under-
went test stimulation. Symptoms of constipation had been
present for a median duration of 10 (range 1–60) years prior
to enrolment. Fifty patients (81%) had slow transit consti-
pation, and 12 (19%) had normal colonic transit.
Forty-four (71%) patients fulfilled the criteria for per-
manent implant, while 18 patients (29%) did not fulfil the
criteria. Of these 44, one patient withdrew from the study
before implant. Two other patients underwent permanent
implantation despite not fulfilling the study implant crite-
ria. These patients were included by errors, and this was
only recognized after data audit. One had previous rectal
prolapse surgery and the second patient had an underlying
neurological disease; hence, these were regarded as pro-
tocol deviation from exclusion criteria. Forty-five patients
underwent permanent implantation, of whom 44 attended
at least one follow-up. One patient experienced leg pain
after permanent implantation and exited the study before
the 1-month follow-up.
Twenty patients (32% of tested patients, 45% of
implanted patients) who had a device implanted or exited
the study prematurely. Seven patients withdrew consent
from the study. Seven patients exited due to loss of effi-
cacy. The mean interval between implantation and loss of
efficacy was 30.3 ± 15.1 months. Six patients were not
available for 60-month follow-up for a site-specific reason.
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Two patients were lost to follow-up. One patient exited
for each of the following reasons: the patient did not fulfil
the inclusion criteria and entered by error, change in
medical condition, faecal incontinence and infection
around the implanted device. Eighteen patients attended
60-month follow-up. The flow of study patients is sum-
marized in Fig. 1.
Bowel diary data
The effects of chronic SNM on constipation symptoms at
follow-up were assessed using the bowel diary. The num-
ber of bowel diaries completed at baseline and test stimu-
lation was 44 out of 62 patients (ITT: 71%), at 48 months
21 out of 22 patients (ITT: 34%, PP: 48%) and 10 out of 18
patients (ITT: 16%, PP: 23%) at 60-month follow-up. The
number of defecations per week increased from 3.3
(0.0–20.3, 4.1 ± 3.7, N = 44) [median (range, mean ± s-
tandard deviation, number of valid diaries)] at baseline to
6.7 (0.6–17.2, 7.3 ± 3.6, N = 41) at test stimulation, 7.0
(1.0–70.0, 10.3 ± 13.9, N = 22) at 48 months and 7.2
(3.0–15.7, 8.1 ± 3.4, N = 10) at 60 months (p\ 0.001)
(Fig. 2). The number of days per week with successful
defecation increased from 2.3 (0.0–7.0, 2.8 ± 2.0, N = 44)
at baseline to 5.0 (0.6–7.0, 4.9 ± 1.7, N = 41) during the
test stimulation, 4.7 (1.0–7.0, 4.7 ± 2.0, N = 22) at the
48-month visit and 5.4 (2.7–7.0, 5.2 ± 1.5, N = 10) at
60 months (p\ 0.001). There were statistically significant
improvement of proportion of successful evacuations, the
average proportion of successful evacuations associated
with a sensation of incomplete emptying, time spent on
toileting per defecation, the number of days with no
abdominal pain or discomfort, and the number of days with
no abdominal bloating all improved at 60 M compared to
baseline. The proportion of spontaneous bowel movements
increased significantly from 0.4 (0.0–1.0, 0.5 ± 0.4) at
baseline to 1.0 (0.0–1.0, 0.9 ± 0.2) during the test stimu-
lation and remained significant for all follow-up visits
(p\ 0.005), except at 1, 12 and 36 months.
Patient subjective assessment of bowel habit was rated
0.08 (0.0–1.0, 0.15 ± 0.22) out of 1 on average at baseline
(0: very poor, 1: very good). The rating improved to 0.77
(0.0–1.0, 0.74 ± 0.24) during the test stimulation, 0.62
(0.01–1.0, 0.55 ± 0.34) at 48 months and 0.85 (0.59–0.93,
0.82 ± 0.1) at 60 months (p\ 0.001). The details of
bowel diary are summarized in Table 1.
Fig. 1 Flow of patients
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The Cleveland Clinic constipation score
Fourteen patients (ITT: 23%, PP: 31%) had both the
baseline and at 60 months CCCS. The Cleveland Clinic
constipation score (0 = no symptoms of constipation to
30 = severe constipation) was 18 (11–27, 17.9 ± 4.4,
N = 42) (median (range, mean ± standard deviation)) at
baseline and 7 (2–19, 8.4 ± 4.2, N = 42) during test
stimulation. The median score was 11 (3–21, mean
11.2 ± 5.1, N = 26) at 48 and 12 (3–17, mean 10.4 ± 4.1,
N = 16) at 60 months. Scores across the follow-up period
were significantly reduced compared to baseline with
p value of less than 0.001. Scores over the follow-up period
are summarized in Fig. 3.
Quality of life
SF-36 questionnaires were available from 38 out of 62
(ITT: 61%) at baseline, 22 out of 22 patients (ITT: 35%,
PP: 50%) at 48 months and 16 out of 18 patients (ITT:
26%, PP: 36%) at 60 months. Quality of life was not
assessed at test stimulation. All SF-36 scores and com-
posite scores improved during test stimulation and after
permanent implant as compared to baseline. The
improvement was maintained over the follow-up period,
but did not reach statistical significance at all follow-up
visits. At 48 and 60 months, the improvement was statis-
tically significant as compared to baseline in the following
domains: physical functioning (p\ 0.02), role physical
(p\ 0.04), bodily pain (p\ 0.001), vitality (p\ 0.001),
social functioning (p\ 0.001) and mental health
(p\ 0.012) as well as for the physical and mental com-
posite scores. Improvement at emotional role was signifi-
cant at 60 months (p\ 0.01). There was no statistically
significant change in the general health at 48 and
60 months and emotional role at 48 months (p[ 0.1)
(Fig. 4).
Anorectal physiological data
The maximal mean resting pressure, maximal mean
squeeze pressure and length of the high pressure zone did
not show a significant difference between baseline, test
stimulation and follow-up assessments. The rectal volumes
for urge, threshold of sensation and maximal tolerated
sensation decreased from baseline for the 1–6-month visits,
but this decrease was not maintained at mid- and long-term
follow-ups (Fig. 5).
Colonic transit study
Thirty-six patients out of 44 who fulfilled the criteria for
permanent implantation had colonic transit time study done
at baseline. Of these patients, 9 patients did not have
colonic transit time at 6 months, leaving only 27 patients
available for comparison between baseline and at
6 months: twenty patients had slow transit, and 7 patients
had normal transit. Of 20 patients with slow transit, 12
patients had normal transit at 6 months, while 8 had per-
sistent slow transit time. Of 7 patients with normal transit,
4 patients remained normal and 3 patients had slow transit
at 6 months.
Of 18 patients who were available for follow-up at
60 months, 13 patients had colonic transit time done both
at baseline and at 6 months. Eleven patients had changed
from slow to normal, 1 patient was normal at baseline and
slow at 6 months, and 1 patient remained slow. A statistical
analysis to evaluate whether the change of transit time
change from baseline to 6 months had any impact on the
outcome at 60 months was attempted but not possible due
to small sample size.
Subgroup analysis
We have conducted a separate analysis of those patients
who attended 60 months follow-up, comparing their base-
line and 60-month data. All the parameters such as the
number of defecations per week (p = 0.016), the number
of days per week with successful defecation (p = 0.02),
proportion of successful evacuations with sensation of
incomplete emptying (p = 0.08), VAS score (p = 0.016)
and Cleveland Clinic constipation score (p = 0.01) and
physical functioning (p = 0.02) of SF36 were improved.
The only subanalysis which altered from the GEE analysis
was the number of natural bowel movements which was
non-significant in the subanalysis (p = 0.156).
Fig. 2 Mean number of defecations per week (mean ± SD) at
baseline (BL), test stimulation and up to 60 months after implant.
(n = number of patients at each follow-up)
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Adverse events
A total of 216 adverse events occurred in 41 (66%) of
tested patients: thirteen of them occurred during testing
phase and 203 events in 39 of 45 implanted patients (87%).
Sixty-four (64) adverse events in 22 (35%) of tested
patients were classified as serious: six of them occurred
before the definitive IPG implantation and 58 after
implantation in 20 of the 45 implanted patients (44%).
The most frequently recorded adverse event (60 events)
was ‘gastrointestinal disorders’ including abdominal pain
(15 events) and constipation (11 events) in 21 patients
(34% of tested patients, 47% of implanted patients). The
second commonest adverse event was classified as ‘generalFig. 3 Change in CCCS score from baseline (mean ± SD). A
negative change indicates decreased severity
Fig. 4 Change in HRQoL
measured with the SF-36 from
baseline
Fig. 5 Change in rectal volumes from baseline to follow-up under SNM
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disorders and administration site conditions’ including
device-related events including computer issues, device
dislocation, lead damage or implant site pain (total 47
events in 23 patients (37% of tested patients, 49% of
implanted patients). This was followed by events catego-
rized as ‘musculoskeletal and connective tissue disorders’
including limb pain/discomfort and musculoskeletal pain
and spasm (36 events) that occurred in 20 patients (32% of
tested patients, 42% of implanted patients).
A total of 122 adverse events were related to the device:
nineteen of them occurred during of after the test period,
and 103 events occurred in 27 (61%) patients after
implantation. Twenty-three (23) events were serious
adverse device effects and were observed in 12 (19%) of
the tested patients, including 17 which occurred after
device implantation in 10 patients (22% of implanted
patients). Serious adverse device effects accounted for 10%
of all adverse events. All adverse device effects and serious
adverse device effects were anticipated adverse events.
One hundred and four events (46% of total events)
occurring in 46 (74%) of tested patients were classified as
not being related to the use of the device.
Four adverse events led to 4 patients (% of implanted
patients) withdrawal from the study. Three (3) of those
were adverse device effects after implantation, and one
patient had infection at connection between the tined lead
and connector to extension lead which eventually led to
withdrawal post-implantation.
Women who were pregnant or considering getting
pregnant were excluded from study participation. However,
3 patients had a total of 5 pregnancies during the course of
the study. Two of those in one patient have been described
previously [11]. One other patient also had two pregnan-
cies. She informed the investigator of her intention to
become pregnant, and the stimulation was turned off prior
to conception for both pregnancies. Two healthy babies
were born at term. In case of the third pregnancy, the
stimulation was turned off at the 5th week of gestation. The
healthy baby was delivered at term. In all pregnancies,
delivery was by caesarian section. At the time of last fol-
low-up, there was no unresolved adverse event.
System modifications
System modification was required on 21 occasions in 14
(31%) patients. Revisions of one of the implanted com-
ponents (neurostimulator, lead, extension) were required on
5 occasions in 4 (9%) patients, replacement on 11 occa-
sions in 10 (22%) patients, and removal of one of the
components on 5 occasions in 3 (7%) patients. Reasons for
system modification were specified for 10 patients as lead
migration on 4 occasions in 4 (9%) patients, infection on 2
occasions in 2 (4%) patients, suspected device problem on
1 occasion in 1 (2%) patient, and other on 12 (63%)
occasions in 10 (22%) patients.
Other data
The number of laxatives used was 1.0 (0.0–8.7, 1.0 ± 1.8,
N = 44) [mean (range, mean ± standard deviation, num-
ber of valid diaries)] at baseline which increased to 2.0
(0.0–15.7, 2.0 ± 4.2, N = 22, ITT: 35%, PP: 49%) at
48 M and 4.3 (0.0–14.3, 4.3 ± 5.4, N = 10, ITT: 16%, PP:
22%) at 60 M.
Discussion
Constipation is a relatively new indication of sacral neu-
romodulation. The current gap in the treatment options for
this condition left clinicians in search of an approach that
would not render patients dependent on chronic laxative
use while eliminating the need for major surgery. Initial
promising results of SNM for constipation [14] led to this
prospective trial.
Thirty-five and 18 of the patients who had been con-
sidered for this treatment were available at 48 and
60 months, and the bowel diary was completed by 22 of
35, and 10 of 18 patients, respectively. Just under 50% of
patients were available for 48-month follow-up which was
further reduced at 60 months partly due to one of the study
sites missing the follow-up window despite that the
patients were still using SNM therapy. This is a small
proportion of the original patient cohort. This illustrates
one of the many challenges of multicentre, long-term
study. Filling in a detailed bowel diary over a long study
period at various time points was a practical challenge, and
we acknowledge that there may be both attrition bias and
reporting bias whereby only those patients who had good
outcome from the therapy filled in bowel diary. As the
study used per protocol analysis by following up only those
patients with the SNM device on and did not include
patients who exited study, it could be argued that there is a
probable bias for the results to be in positive direction
given that the study was also uncontrolled and the patients
knew they were on active treatment. However, analysis of
those who exited the trial was not possible due to regula-
tory binding that we are obliged to report this trial outcome
as per protocol.
It is also not possible to ascertain whether patients who
benefitted long term did so because of the SNM or other
factors. Laxative use at 5 years was similar to baseline.
Data on dose were only reported anecdotally so that no
comparison on the amount of laxatives used could be done.
Nevertheless, the continued use of laxatives at 48 and
60 months suggests that although symptoms were
284 Tech Coloproctol (2017) 21:277–286
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improved on long-term follow-up, there was still a need for
supplementary therapy.
The mechanisms of action of SNM for constipation
remain obscure. A recently published study [15] postulated
that SNM may normalize rectal hyposensitivity in patients
with evacuatory dysfunction. Our findings showed a
reduction of maximum volume at 3 months, but this effect
was lost afterwards. Rectal sensory volumes were similar at
60 months to baseline. Suprasensory stimulation (a stimu-
lation above sensory perception threshold) has been shown
to increase colonic propagation which suggests the SNM
affects afferent pathway modulation [16] although the
precise mechanism is unclear. A recent randomized con-
trolled trial by the same authors, however, showed no
difference in the number of complete bowel movements
between sham, subsensory and suprasensory stimulation
[17]. Although it is likely that SNM modulates both local
and central pathways, data to date are too sparse to allow a
meaningful understanding of the association between the
physiological findings and improvement of clinical
symptoms.
A recent study showed the underlying type of con-
stipation does not influence the outcome of SNM [18].
The current study did not allow us to determine whether
those with predominantly slow transit or evacuation
difficulties benefited more from SNM. This is because
the number of patients who were available at 60 months
was small. There were also a few patients who continued
this therapy beyond 60 months but were treated as exited
the study due to failure to follow-up at the trial window,
and thus, such analysis in this study is likely to bias the
outcome.
Adverse events were recorded stringently, and this is
reflected in a fact that most of the participants experienced
an adverse event. However, these were mostly minor or
related to the constipation per se and there was no mortality
associated with the therapy. In about one-third of the
patients, device-related adverse events required modifica-
tion of the system including revisions, replacement or
removal of whole or part of the system. The potential need
for revisional surgery during the course of therapy should
be explained to patients prior to implantation. The clinical
and financial impact of this maintenance aspect should be
considered and compared to the clinical and financial
impact of other treatment alternatives when including SNM
in a clinical service set-up.
The role of SNM within the treatment algorithm and the
clinical treatment pathway for chronic constipation in
comparison with other options, as well as patient selection
criteria, is unclear. Recent randomized double-blind
crossover studies have shown no difference between active
and sham stimulations [17, 19]. In both studies, 30–60% of
patients had a positive response during sham stimulation,
suggestive of either lasting effects of sensory stimulation
beyond washout period between sham and active treatment
(2–3 weeks) or high placebo effects of this treatment. In
the light of these results from the well-designed random-
ized trials, it is difficult to recommend sacral neuromodu-
lation as a treatment within a treatment algorithm of
constipation.
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